Taiwan's Drugs Bill Tops $1.8 Billion For 1996

24 November 1997

For 1996, Taiwan's National Bureau of Health insurance unit spent someNT$57.6 billion ($1.84 billion) on drugs consumed in the country, which reflects per capita consumption of medicines at NT$2,000 last year.

NBH statistics (produced in cooperation with the pharmaceutical industry) indicate that the most used products were gastrointestinal medicines and vitamins, accounting for NT$10.7 billion, with antibiotics at NT$7.5 billion and cardiovascular drugs at NT$6.7 billion. The figures, quoted in The China Post, also note that last year's consumption of blood-related medicines rose 26% over 1995, while the consumption of central nervous system drugs increased 22%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.